Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Tolllike receptor agonists

Soraya Zorro Manrique, Ana L. Dominguez, Noweeda Mirza, Christopher D. Spencer, Judy M. Bradley, James H. Finke, James J. Lee, Larry R Pease, Sandra J Gendler, Peter A Cohen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Many cancers both evoke and subvert endogenous anti-tumor immunity. However, immunosuppression can be therapeutically reversed in subsets of cancer patients by treatments such as checkpoint inhibitors or Toll-like receptor agonists (TLRa). Moreover, chemotherapy can leukodeplete immunosuppressive host elements, including myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs). We hypothesized that chemotherapy-induced leukodepletion could be immunopotentiated by co-administering TLRa to emulate a life-threatening infection. Combining CpG (ODN 1826) or CpG+poly(I:C) with cyclophosphamide (CY) resulted in uniquely well-tolerated therapeutic synergy, permanently eradicating advanced mouse tumors including 4T1 (breast), Panc02 (pancreas) and CT26 (colorectal). Definitive treatment required endogenous CD8+ and CD4+ IFNγ-producing T-cells. Tumorspecific IFNγ-producing T-cells persisted during CY-induced leukopenia, whereas Tregs were progressively eliminated, especially intratumorally. Spleen-associated MDSCs were cyclically depleted by CY+TLRa treatment, with residual monocytic MDSCs requiring only continued exposure to CpG or CpG+IFNγ to effectively attack malignant cells while sparing non-transformed cells. Such tumor destruction occurred despite upregulated tumor expression of Programmed Death Ligand-1, but could be blocked by clodronate-loaded liposomes to deplete phagocytic cells or by nitric oxide synthase inhibitors. CY+TLRa also induced tumoricidal myeloid cells in naive mice, indicating that CY+TLRa's immunomodulatory impacts occurred in the complete absence of tumor-bearing, and that tumor-induced MDSCs were not an essential source of tumoricidal myeloid precursors. Repetitive CY+TLRa can therefore modulate endogenous immunity to eradicate advanced tumors without vaccinations or adoptive T-cell therapy. Human blood monocytes could be rendered similarly tumoricidal during in vitro activation with TLRa+IFNγ, underscoring the potential therapeutic relevance of these mouse tumor studies to cancer patients.

Original languageEnglish (US)
Pages (from-to)42919-42942
Number of pages24
JournalOncotarget
Volume7
Issue number28
DOIs
StatePublished - 2016

Fingerprint

Cyclophosphamide
Immunity
Toll-Like Receptors
Neoplasms
T-Lymphocytes
Clodronic Acid
Therapeutics
Drug Therapy
Leukopenia
Regulatory T-Lymphocytes
Myeloid Cells
Immunosuppressive Agents
Phagocytes
Cell- and Tissue-Based Therapy
Liposomes
Nitric Oxide Synthase
Immunosuppression
Monocytes
Pancreas
Vaccination

Keywords

  • Cancer immunotherapy
  • Chemotherapy
  • Immune response
  • Immunity
  • Immunology and Microbiology Section
  • MDSCs
  • TLR agonists
  • Tregs

ASJC Scopus subject areas

  • Oncology

Cite this

Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Tolllike receptor agonists. / Manrique, Soraya Zorro; Dominguez, Ana L.; Mirza, Noweeda; Spencer, Christopher D.; Bradley, Judy M.; Finke, James H.; Lee, James J.; Pease, Larry R; Gendler, Sandra J; Cohen, Peter A.

In: Oncotarget, Vol. 7, No. 28, 2016, p. 42919-42942.

Research output: Contribution to journalArticle

Manrique, Soraya Zorro ; Dominguez, Ana L. ; Mirza, Noweeda ; Spencer, Christopher D. ; Bradley, Judy M. ; Finke, James H. ; Lee, James J. ; Pease, Larry R ; Gendler, Sandra J ; Cohen, Peter A. / Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Tolllike receptor agonists. In: Oncotarget. 2016 ; Vol. 7, No. 28. pp. 42919-42942.
@article{6b1658264ad54b98b549db3e0af132ca,
title = "Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Tolllike receptor agonists",
abstract = "Many cancers both evoke and subvert endogenous anti-tumor immunity. However, immunosuppression can be therapeutically reversed in subsets of cancer patients by treatments such as checkpoint inhibitors or Toll-like receptor agonists (TLRa). Moreover, chemotherapy can leukodeplete immunosuppressive host elements, including myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs). We hypothesized that chemotherapy-induced leukodepletion could be immunopotentiated by co-administering TLRa to emulate a life-threatening infection. Combining CpG (ODN 1826) or CpG+poly(I:C) with cyclophosphamide (CY) resulted in uniquely well-tolerated therapeutic synergy, permanently eradicating advanced mouse tumors including 4T1 (breast), Panc02 (pancreas) and CT26 (colorectal). Definitive treatment required endogenous CD8+ and CD4+ IFNγ-producing T-cells. Tumorspecific IFNγ-producing T-cells persisted during CY-induced leukopenia, whereas Tregs were progressively eliminated, especially intratumorally. Spleen-associated MDSCs were cyclically depleted by CY+TLRa treatment, with residual monocytic MDSCs requiring only continued exposure to CpG or CpG+IFNγ to effectively attack malignant cells while sparing non-transformed cells. Such tumor destruction occurred despite upregulated tumor expression of Programmed Death Ligand-1, but could be blocked by clodronate-loaded liposomes to deplete phagocytic cells or by nitric oxide synthase inhibitors. CY+TLRa also induced tumoricidal myeloid cells in naive mice, indicating that CY+TLRa's immunomodulatory impacts occurred in the complete absence of tumor-bearing, and that tumor-induced MDSCs were not an essential source of tumoricidal myeloid precursors. Repetitive CY+TLRa can therefore modulate endogenous immunity to eradicate advanced tumors without vaccinations or adoptive T-cell therapy. Human blood monocytes could be rendered similarly tumoricidal during in vitro activation with TLRa+IFNγ, underscoring the potential therapeutic relevance of these mouse tumor studies to cancer patients.",
keywords = "Cancer immunotherapy, Chemotherapy, Immune response, Immunity, Immunology and Microbiology Section, MDSCs, TLR agonists, Tregs",
author = "Manrique, {Soraya Zorro} and Dominguez, {Ana L.} and Noweeda Mirza and Spencer, {Christopher D.} and Bradley, {Judy M.} and Finke, {James H.} and Lee, {James J.} and Pease, {Larry R} and Gendler, {Sandra J} and Cohen, {Peter A}",
year = "2016",
doi = "10.18632/oncotarget.10190",
language = "English (US)",
volume = "7",
pages = "42919--42942",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "28",

}

TY - JOUR

T1 - Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Tolllike receptor agonists

AU - Manrique, Soraya Zorro

AU - Dominguez, Ana L.

AU - Mirza, Noweeda

AU - Spencer, Christopher D.

AU - Bradley, Judy M.

AU - Finke, James H.

AU - Lee, James J.

AU - Pease, Larry R

AU - Gendler, Sandra J

AU - Cohen, Peter A

PY - 2016

Y1 - 2016

N2 - Many cancers both evoke and subvert endogenous anti-tumor immunity. However, immunosuppression can be therapeutically reversed in subsets of cancer patients by treatments such as checkpoint inhibitors or Toll-like receptor agonists (TLRa). Moreover, chemotherapy can leukodeplete immunosuppressive host elements, including myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs). We hypothesized that chemotherapy-induced leukodepletion could be immunopotentiated by co-administering TLRa to emulate a life-threatening infection. Combining CpG (ODN 1826) or CpG+poly(I:C) with cyclophosphamide (CY) resulted in uniquely well-tolerated therapeutic synergy, permanently eradicating advanced mouse tumors including 4T1 (breast), Panc02 (pancreas) and CT26 (colorectal). Definitive treatment required endogenous CD8+ and CD4+ IFNγ-producing T-cells. Tumorspecific IFNγ-producing T-cells persisted during CY-induced leukopenia, whereas Tregs were progressively eliminated, especially intratumorally. Spleen-associated MDSCs were cyclically depleted by CY+TLRa treatment, with residual monocytic MDSCs requiring only continued exposure to CpG or CpG+IFNγ to effectively attack malignant cells while sparing non-transformed cells. Such tumor destruction occurred despite upregulated tumor expression of Programmed Death Ligand-1, but could be blocked by clodronate-loaded liposomes to deplete phagocytic cells or by nitric oxide synthase inhibitors. CY+TLRa also induced tumoricidal myeloid cells in naive mice, indicating that CY+TLRa's immunomodulatory impacts occurred in the complete absence of tumor-bearing, and that tumor-induced MDSCs were not an essential source of tumoricidal myeloid precursors. Repetitive CY+TLRa can therefore modulate endogenous immunity to eradicate advanced tumors without vaccinations or adoptive T-cell therapy. Human blood monocytes could be rendered similarly tumoricidal during in vitro activation with TLRa+IFNγ, underscoring the potential therapeutic relevance of these mouse tumor studies to cancer patients.

AB - Many cancers both evoke and subvert endogenous anti-tumor immunity. However, immunosuppression can be therapeutically reversed in subsets of cancer patients by treatments such as checkpoint inhibitors or Toll-like receptor agonists (TLRa). Moreover, chemotherapy can leukodeplete immunosuppressive host elements, including myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs). We hypothesized that chemotherapy-induced leukodepletion could be immunopotentiated by co-administering TLRa to emulate a life-threatening infection. Combining CpG (ODN 1826) or CpG+poly(I:C) with cyclophosphamide (CY) resulted in uniquely well-tolerated therapeutic synergy, permanently eradicating advanced mouse tumors including 4T1 (breast), Panc02 (pancreas) and CT26 (colorectal). Definitive treatment required endogenous CD8+ and CD4+ IFNγ-producing T-cells. Tumorspecific IFNγ-producing T-cells persisted during CY-induced leukopenia, whereas Tregs were progressively eliminated, especially intratumorally. Spleen-associated MDSCs were cyclically depleted by CY+TLRa treatment, with residual monocytic MDSCs requiring only continued exposure to CpG or CpG+IFNγ to effectively attack malignant cells while sparing non-transformed cells. Such tumor destruction occurred despite upregulated tumor expression of Programmed Death Ligand-1, but could be blocked by clodronate-loaded liposomes to deplete phagocytic cells or by nitric oxide synthase inhibitors. CY+TLRa also induced tumoricidal myeloid cells in naive mice, indicating that CY+TLRa's immunomodulatory impacts occurred in the complete absence of tumor-bearing, and that tumor-induced MDSCs were not an essential source of tumoricidal myeloid precursors. Repetitive CY+TLRa can therefore modulate endogenous immunity to eradicate advanced tumors without vaccinations or adoptive T-cell therapy. Human blood monocytes could be rendered similarly tumoricidal during in vitro activation with TLRa+IFNγ, underscoring the potential therapeutic relevance of these mouse tumor studies to cancer patients.

KW - Cancer immunotherapy

KW - Chemotherapy

KW - Immune response

KW - Immunity

KW - Immunology and Microbiology Section

KW - MDSCs

KW - TLR agonists

KW - Tregs

UR - http://www.scopus.com/inward/record.url?scp=84978641584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978641584&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10190

DO - 10.18632/oncotarget.10190

M3 - Article

C2 - 27341020

AN - SCOPUS:84978641584

VL - 7

SP - 42919

EP - 42942

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -